Ticker Hub
GILD — AI Analysis & Sentiment
11 recent AI-generated analyses for GILD. Sentiment and confidence insights updated continuously.
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
Gilead's Livdelzi for PBC demonstrated positive long-term Phase 3 interim results, strengthening its market position for an already approved drug. ...
May 27, 2026FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Gilead's FDA accelerated approval of Hepcludex, the first and only treatment for chronic HDV, provides a new revenue stream and addresses a high un...
May 22, 2026Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Gilead's Trodelvy receiving a positive CHMP opinion for first-line metastatic TNBC enhances its oncology market position and revenue potential. Thi...
May 22, 2026New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Gilead's upcoming presentations of new clinical data for its oncology programs at ASCO and EHA 2026 signal robust pipeline progression, strengtheni...
May 21, 2026Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Gilead has strategically expanded its oncology pipeline with the definitive acquisition of Tubulis, integrating promising next-generation ADC asset...
May 21, 2026U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
The FDA's priority review for Gilead's bictegravir plus lenacapavir HIV treatment marks a significant regulatory milestone. This positive developme...
Apr 29, 2026Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
Gilead's strategic acquisition of Arcellx for $7.8 billion, securing the anito-cel CAR T-cell therapy, enhances its oncology pipeline. This move, w...
Apr 28, 2026Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
Gilead's receipt of all regulatory approvals for the Arcellx acquisition significantly de-risks the deal, bolstering its oncology franchise and cre...
Apr 17, 2026Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Gilead's acquisition of Ouro Medicines adds a promising clinical-stage T cell engager for autoimmune diseases to its pipeline. This strategic move,...
Mar 23, 2026Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
The Gilead Foundation announced a $12 million grant to support community health workers and HIV prevention across 14 states. This funding could enh...
Mar 2, 2026Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
Gilead's positive clinical data reinforces its strong position in the HIV market, supporting its long-term growth trajectory. This news provides a ...
Feb 27, 2026